Hamidreza Komaki

Hamidreza Komaki

Auto-generated profile, based on publicly available information

Hamidreza Komaki

Neurophysiology Research Center, Hamadan University of Medical Sciences, Hamadan, Iran

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2019 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
GCGlobal Burden of Disease Cancer Collaboration
Global Burden of Disease Cancer Collaboration
CFChristina Fitzmaurice
Christina Fitzmaurice
DADegu Abate
Degu Abate
NANaghmeh Abbasi
Naghmeh Abbasi
HAHedayat Abbastabar
Hedayat Abbastabar
CMChristopher J. L. Murray
Christopher J. L. Murray
Cancer is now widely recognized as a global problem that unfortunately lacks a global solution. The latest United Nations high-level meeting on noncommunicable diseases (NCDs) exemplified this conundrum.1 Despite global commitment to reducing the risk of and disability from NCDs, including cancer, implementation of known solutions is inadequate to reach the 2011 Political Declaration on the Prevention and Control of Noncommunicable Diseases2,3 (25% reduction in premature mortality from NCDs by 2025) and the third Sustainable Development Goal (by 2030 reduce by one-third premature mortality from NCDs through prevention and treatment, and promote mental health and well-being).4 To reduce cancer burden, identifying the scope of the problem and mapping out implementation of solutions is best done in National Cancer Control Plans (NCCPs). However, a recent review showed that only 29% of low-income countries had a NCCP, and even if NCCPs existed, cost, financing, monitoring, and expansion of information systems was often inadequate. Many highly effective prevention and treatment strategies exist for cancer. However, they are often very specific (eg, vaccination for human papillomavirus and hepatitis B virus for prevention of cervical and liver cancer, or tyrosine kinase inhibitors for cancers with targetable mutations). Effective NCCPs therefore require detailed knowledge about the local burden of cancer and associated risk factors. We herein present results from the Global Burden of Disease (GBD) 2017 study describing cancer incidence, mortality, years of life lost (YLLs), years lived with disability (YLDs), and disability-adjusted life-years (DALYs) for 195 countries from 1990 through 2017, which can inform cancer control through policy, resource allocation, and health system planning.

1 December 2019 in The Lancet Gastroenterology & Hepatology
Verified
Journal Article
Open access
SSSaeid Safiri
Saeid Safiri
SSSadaf G Sepanlou
Sadaf G Sepanlou
KIKevin S Ikuta
Kevin S Ikuta
CBCatherine Bisignano
Catherine Bisignano
HSHamideh Salimzadeh
Hamideh Salimzadeh
RMReza Malekzadeh
Reza Malekzadeh
Data about the global, regional, and country-specific variations in the levels and trends of colorectal cancer are required to understand the impact of this disease and the trends in its burden to help policy makers allocate resources. Here we provide a status report on the incidence, mortality, and disability caused by colorectal cancer in 195 countries and territories between 1990 and 2017. Vital registration, sample vital registration, verbal autopsy, and cancer registry data were used to generate incidence, death, and disability-adjusted life-year (DALY) estimates of colorectal cancer at the global, regional, and national levels. We also determined the association between development levels and colorectal cancer age-standardised DALY rates, and calculated DALYs attributable to risk factors that had evidence of causation with colorectal cancer. All of the estimates are reported as counts and age-standardised rates per 100 000 person-years, with some estimates also presented by sex and 5-year age groups. In 2017, there were 1·8 million (95% UI 1·8-1·9) incident cases of colorectal cancer globally, with an age-standardised incidence rate of 23·2 (22·7-23·7) per 100 000 person-years that increased by 9·5% (4·5-13·5) between 1990 and 2017. Globally, colorectal cancer accounted for 896 000 (876 300-915 700) deaths in 2017, with an age-standardised death rate of 11·5 (11·3-11·8) per 100 000 person-years, which decreased between 1990 and 2017 (-13·5% [-18·4 to -10·0]). Colorectal cancer was also responsible for 19·0 million (18·5-19·5) DALYs globally in 2017, with an age-standardised rate of 235·7 (229·7-242·0) DALYs per 100 000 person-years, which decreased between 1990 and 2017 (-14·5% [-20·4 to -10·3]). Slovakia, the Netherlands, and New Zealand had the highest age-standardised incidence rates in 2017. Greenland, Hungary, and Slovakia had the highest age-standardised death rates in 2017. Numbers of incident cases and deaths were higher among males than females up to the ages of 80-84 years, with the highest rates observed in the oldest age group (≥95 years) for both sexes in 2017. There was a non-linear association between the Socio-demographic Index and the Healthcare Access and Quality Index and age-standardised DALY rates. In 2017, the three largest contributors to DALYs at the global level, for both sexes, were diet low in calcium (20·5% [12·9-28·9]), alcohol use (15·2% [12·1-18·3]), and diet low in milk (14·3% [5·1-24·8]). There is substantial global variation in the burden of colorectal cancer. Although the overall colorectal cancer age-standardised death rate has been decreasing at the global level, the increasing age-standardised incidence rate in most countries poses a major public health challenge across the world. The results of this study could be useful for policy makers to carry out cost-effective interventions and to reduce exposure to modifiable risk factors, particularly in countries with high incidence or increasing burden. Bill & Melinda Gates Foundation.

1 April 2019 in Brain Research Bulletin
Verified
Journal Article
Closed access
HKHamidreza Komaki
Hamidreza Komaki
NFNafiseh Faraji
Nafiseh Faraji
AKAlireza Komaki
Alireza Komaki
SSSiamak Shahidi
Siamak Shahidi
FEFarshid Etaed
Farshid Etaed
FMFatemeh Mirzaei
Fatemeh Mirzaei

1 July 2015 in Brain Research Bulletin
Verified
Journal Article
Closed access
RKRuhollah Karamian
Ruhollah Karamian
AKAlireza Komaki
Alireza Komaki
ISIraj Salehi
Iraj Salehi
LTLida Tahmasebi
Lida Tahmasebi
HKHamidreza Komaki
Hamidreza Komaki
ASAbdolrahman Sarihi
Abdolrahman Sarihi

1 May 2017 in Brain Research Bulletin
Verified
Journal Article
Closed access
HKHamidreza Komaki
Hamidreza Komaki
FSFargol Saadat
Fargol Saadat
SSSiamak Shahidi
Siamak Shahidi
ASAbdolrahman Sarihi
Abdolrahman Sarihi
PHParisa Hasanein
Parisa Hasanein
AKAlireza Komaki
Alireza Komaki

1 July 2016 in Brain Research
Verified
Journal Article
Closed access
LTLida Tahmasebi
Lida Tahmasebi
AKAlireza Komaki
Alireza Komaki
RKRuhollah Karamian
Ruhollah Karamian
SSSiamak Shahidi
Siamak Shahidi
ASAbdolrahman Sarihi
Abdolrahman Sarihi
HKHamidreza Komaki
Hamidreza Komaki